** Shares of drug developer Compass Therapeutics CMPX.O fall 14.5% to $1.62
** CMPX says its experimental biliary tract cancer drug, tovecimig, when combined with chemotherapy, showed an overall response rate $(ORR.AU)$ of 17.1% in patients compared to 5.3% who received chemotherapy alone
** ORR is the proportion of patients whose tumors reduced in size or disappeared over a predefined period of time
** Brokerage Leerink Partners says this response rate is lower than expected, and lower than what was seen in previous trials
** Other treatments, such as Enhertu by AstraZeneca AZN.L and Pemazyre by Incyte INCY.O, have shown higher response rates in similar patient populations, brokerage says
** Including sessions moves, CMPX stock up 31% YTD
(Reporting by Padmanabhan Ananthan)
((padmanabhan.ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。